牙周治疗市场 - 副产品（局部抗生素治疗、全身性抗生素治疗）、类型（牙龈炎、慢性牙周病、侵袭性牙周病）、配销通路- 全球预测（2024 - 2032）

在牙周病盛行率上升的推动下，2024年至2032年牙周治疗市场规模将以7.7%的复合年增长率成长。根据世界卫生组织 2023 年 3 月发布的口腔健康报告，估计全球约 19% 的成年人口患有严重的牙周疾病。口腔卫生不良、吸烟和糖尿病等全身健康问题等因素导致这些疾病的负担日益加剧。因此，对有效治疗解决方案的需求激增，促使对先进牙周治疗的开发和实施进行大量投资。

个人化治疗计画的出现是塑造市场的重要趋势。牙科诊断和患者资料分析的进步使医生能够根据患者的个人资料（包括其基因组成、疾病严重程度和整体健康状况）量身定制治疗方案。这种向个人化护理的转变透过满足患者的特定需求和偏好、改善结果和满意度来提高治疗效果。个人化治疗计划通常结合标靶治疗、先进诊断和客製化预防措施，使牙周护理更加有效并以患者为中心。

牙周治疗产业根据产品、类型、配销通路和地区进行分类。

到 2032 年，局部抗生素治疗领域将快速成长。这种方法可以进行有针对性的治疗，最大限度地减少全身副作用并提高牙周护理的整体效果。局部抗生素製剂和递送机制（例如控释系统）的最新进展预计将推动该领域的成长。

到 2032 年，侵袭性牙周病领域将出现良好增长。这种情况需要及时有效的治疗干预，以防止严重后果，包括牙齿脱落。不断上升的发病率推动了对这种严重牙周炎的先进治疗方案的需求。旨在控制疾病进展和促进组织再生的治疗对于满足侵袭性牙周病患者的需求至关重要。

在多种因素的推动下，欧洲牙周治疗产业将在 2032 年实现强劲成长。该地区完善的医疗基础设施和高标准的牙科护理有助于越来越多地采用先进的牙周治疗。欧洲国家的牙周病发生率也不断上升，促使人们加大对治疗解决方案的投资。此外，持续的研发工作正在引入用于疾病管理的创新产品和技术，进一步推动区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 牙周病盛行率不断上升
    • 提高口腔健康意识
    • 老年人口不断增加
    • 牙科技术进步
  • 产业陷阱与挑战
    • 对口腔健康的认知与教育有限
    • 严格的监理政策
• 成长潜力分析
• 报销场景
• 监管环境
• 技术景观
  • 核心技术
  • 邻近技术
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

• 主要趋势
• 局部抗生素治疗
  • 盐酸米诺环素
  • 盐酸多西环素
  • 葡萄糖酸氯己定
  • 甲硝唑苯甲酸盐
  • 盐酸四环素
• 全身性抗生素治疗
  • 盐酸米诺环素
  • 盐酸多西环素
  • 甲硝唑苯甲酸盐

第 6 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 牙龈炎
• 慢性牙周病
• 侵袭性牙周病
• 坏死性牙周病
• 其他类型

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 药局
• 电子商务

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Align Technology, Inc.
• Bausch Health Companies Inc.
• Cadila Healthcare Ltd.
• Colgate-Palmolive Company
• Danaher Corporation
• Den-Mat Holdings LLC
• Dentsply Sirona
• Dexcel Pharma Technologies Ltd.
• GlaxoSmithKline plc
• Henry Schein, Inc.
• Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Kaken Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Procter & Gamble Co.
• Straumann Holding AG
• Sunstar Suisse SA
• Teva Pharmaceutical Industries Ltd.
• Zimmer Biomet Holdings, Inc.
• 3M Company

The Periodontal Therapeutics Market size will grow at 7.7% CAGR during 2024-2032, driven by the rising prevalence of periodontal diseases. According to a WHO Oral Health report published in March 2023, severe periodontal ailments are estimated to impact approximately 19% of the global adult population. Factors such as poor oral hygiene, smoking, and systemic health issues like diabetes contribute to the growing burden of these diseases. As a result, there is a surge in demand for effective therapeutic solutions, prompting significant investment in the development and delivery of advanced periodontal treatments.

The emergence of personalized treatment plans is a significant trend shaping the market. Advances in dental diagnostics and patient data analysis are enabling practitioners to tailor treatments based on individual patient profiles, including their genetic makeup, disease severity, and overall health conditions. This shift towards personalized care enhances treatment efficacy by addressing specific needs and preferences of patients, improving outcomes and satisfaction. Personalized treatment plans often incorporate a combination of targeted therapies, advanced diagnostics, and customized preventive measures, making periodontal care more effective and patient centric.

The periodontal therapeutics industry is classified based on product, type, distribution channel, and region.

The local antibiotic therapy segment will grow rapidly through 2032. Local antibiotic therapy involves the direct application of antimicrobial agents to the periodontal pocket to control bacterial infections and reduce inflammation. This approach allows for targeted treatment, minimizing systemic side effects and enhancing the overall effectiveness of periodontal care. Recent advancements in local antibiotic formulations and delivery mechanisms, such as controlled-release systems, are expected to drive growth in this segment.

The aggressive periodontal disease segment will witness decent growth through 2032. Aggressive periodontal disease, characterized by rapid attachment loss and bone destruction, poses a serious challenge to oral health. This condition requires prompt and effective therapeutic interventions to prevent severe consequences, including tooth loss. The increasing incidence rate is driving demand for advanced treatment options tailored to managing this severe form of periodontitis. Therapies aimed at controlling the disease's progression and promoting tissue regeneration are crucial in addressing the needs of patients with aggressive periodontal conditions.

Europe periodontal therapeutics industry will witness robust growth through 2032, driven by a combination of factors. The region's well-established healthcare infrastructure and high standards of dental care contribute to the increasing adoption of advanced periodontal treatments. European countries are also experiencing a rising incidence of periodontal diseases, which is prompting greater investment in therapeutic solutions. Moreover, ongoing R&D efforts are leading to the introduction of innovative products and technologies for disease management, further fueling the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360°synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of periodontal diseases
    • 3.2.1.2 Increasing awareness about oral health
    • 3.2.1.3 Rising geriatric population
    • 3.2.1.4 Technological advancements in dentistry
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited awareness and education for oral health
    • 3.2.2.2 Stringent regulatory policies
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
  • 3.6.1 Core technologies
  • 3.6.2 Adjacent technologies
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Local antibiotic therapy
  • 5.2.1 Minocycline hydrochloride
  • 5.2.2 Doxycycline hyclate
  • 5.2.3 Chlorhexidine gluconate
  • 5.2.4 Metronidazole benzoate
  • 5.2.5 Tetracycline hydrochloride
• 5.3 Systemic antibiotic therapy
  • 5.3.1 Minocycline hydrochloride
  • 5.3.2 Doxycycline hyclate
  • 5.3.3 Metronidazole benzoate

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Gingivitis
• 6.3 Chronic periodontal disease
• 6.4 Aggressive periodontal disease
• 6.5 Necrotizing periodontal disease
• 6.6 Other types

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Drug stores
• 7.5 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Align Technology, Inc.
• 9.2 Bausch Health Companies Inc.
• 9.3 Cadila Healthcare Ltd.
• 9.4 Colgate-Palmolive Company
• 9.5 Danaher Corporation
• 9.6 Den-Mat Holdings LLC
• 9.7 Dentsply Sirona
• 9.8 Dexcel Pharma Technologies Ltd.
• 9.9 GlaxoSmithKline plc
• 9.10 Henry Schein, Inc.
• 9.11 Hoffmann-La Roche Ltd.
• 9.12 Johnson & Johnson Services, Inc.
• 9.13 Kaken Pharmaceutical Co., Ltd.
• 9.14 Pfizer Inc.
• 9.15 Procter & Gamble Co.
• 9.16 Straumann Holding AG
• 9.17 Sunstar Suisse SA
• 9.18 Teva Pharmaceutical Industries Ltd.
• 9.19 Zimmer Biomet Holdings, Inc.
• 9.20 3M Company